Skip to main content
SpringerLink
Log in

Course of Crohn’s Disease

  • Chapter
  • First Online:
Crohn’s Disease

  • 1262 Accesses

Abstract

Crohn’s disease (CD) is an inflammatory bowel disease with a chronic course and it is characterized by different events within time, which are in relation to the heterogeneity of the disease. The main events during the course of disease are activity, remission, relapse, obstruction, fistulizing, surgical resection, cancer and death. Unselected inception cohort studies are the best ones on which rely in order to avoid the selection bias from referral centers. Data produced using inception-cohort have shown a more benign course of CD than expected, an increased risk of surgery over time, with a trend which has been being reduced in the last decades, together with an increased use of biologics and immunosuppressants. The clinical features of CD change over time with a decreasing frequency of inflammatory disease behavior and an increasing frequency of stricturing and /or penetrating disease behavior, it is possible to identify the main predictors of a disabling course. An increased risk of colorectal cancer and small bowel cancer, lymphoproliferative disorders, non-melanoma skin cancer, have been described in CD. However the risk of dying in CD patient when compared with general population is higher, even if in inception-cohort studies the increased risk is not always detectable.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Crohn BB, Ginzburg L, Oppenheimer GD. (From the Mount Sinai Hospital New York) “Regional Ileitis” A pathologic and clinical entity. JAMA. 1932;99:1323–8.

    Article  Google Scholar 

  2. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13(4):481–9.

    Article  PubMed  Google Scholar 

  3. Jess T, Winther KV, Munkholm P, et al. Mortality and causes of death in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology. 2002;122(7):1808–14.

    Article  PubMed  Google Scholar 

  4. Jess T, Loftus Jr EV, Harmsen WS, et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940–2004. Gut. 2006;55(9):1248–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Palli D, Trallori G, Masala G. General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence Study. Gut. 1998;42(2):175–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Sackett DL, Hayness RB, Guyatt G, Tugwell P. Clinical epidemiology. A basic science for clinical medicine. 2nd ed. London: Little, Brown and Company; 1991.

    Google Scholar 

  7. Cosnes J, Bourrier A, Nion-Larmurier I, et al. Factors affecting outcomes in Crohn’s disease over 15 years. Gut. 2012;61:1140–5.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lakatos PL, Golovics PA, David G, et al. Has there been a change in the natural history of Crohn’s disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977–2009. Am J Gastroenterol. 2012;107:579–88.

    Article  CAS  PubMed  Google Scholar 

  9. Persson PG, Bernell O, Leijonmarck CE, et al. Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology. 1996;110(5):1339–45.

    Article  CAS  PubMed  Google Scholar 

  10. Sjöberg D, Holmström T, Larsson M, et al. Incidence and clinical course of Crohn’s disease during the first year – results from the IBD Cohort of the Uppsala Region (ICURE) of Sweden 2005–2009. J Crohns Colitis. 2014;8(3):215–22.

    Article  PubMed  Google Scholar 

  11. Canavan C, Abrams KR, Mayberry JF, et al. Meta-analysis: mortality in Crohn’s disease. Aliment Pharmacol Ther. 2007;25:861–70.

    Article  CAS  PubMed  Google Scholar 

  12. Uno H, Yao T, Matsui T, Sakurai T, et al. Mortality and cause of death in Japanese patients with Crohn’s disease. Dis Colon Rectum. 2003;46(10 Suppl):S15–21.

    PubMed  Google Scholar 

  13. Chatu S, Saxena S, Subramanian V, et al. The impact of timing and duration of thiopurine treatment on first intestinal resection in Crohn’s Disease: national UK population-based study 1989–2010. Am J Gastroenterol. 2014;109:409–16.

    Article  CAS  PubMed  Google Scholar 

  14. Masala G, Bagnoli S, Ceroti M, et al. Divergent patterns of total and cancer mortality in ulcerative colitis and Crohn’s disease patients: the Florence IBD study 1978–2001. Gut. 2004;53(9):1309–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322–38.

    Article  CAS  PubMed  Google Scholar 

  16. Peyrin-Biroulet L, Loftus Jr EV, Colombel J-F, et al. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut. 2010;59:141–7.

    Article  CAS  PubMed  Google Scholar 

  17. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut. 2005;54:237–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Renna S, Cammà C, Modesto I, et al. Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn’s disease. Gastroenterology. 2008;135(5):1500–9.

    Article  CAS  PubMed  Google Scholar 

  19. Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979–2011. Gut. 2014;63:1607–16.

    Article  CAS  PubMed  Google Scholar 

  20. Ananthakrishnan AN, McGinley EL, et al. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. 2009;15:182–9.

    Article  PubMed  Google Scholar 

  21. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117:49–57.

    Article  CAS  PubMed  Google Scholar 

  22. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol. 1995;30:699–706.

    Article  CAS  PubMed  Google Scholar 

  23. Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430–8.

    Article  PubMed  Google Scholar 

  24. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn’s disease: a population-based cohort study. Gastroenterology. 2008;135:1106–13.

    Article  PubMed  Google Scholar 

  25. D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371:660.

    Article  PubMed  Google Scholar 

  26. Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebocontrolled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease. J Crohn’s Colitis. 2013;7:213–21.

    Article  CAS  Google Scholar 

  27. Abraham NS, Richardson P, Castillo D, et al. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(10):1281–7.

    Article  CAS  PubMed  Google Scholar 

  28. Frolkis AD, Dykeman J, Negrón ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996–1006.

    Article  PubMed  Google Scholar 

  29. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, et al. Surgery in a population-based cohort of Crohn’s disease from Olmsted County, Minnesota (1970–2004). Am J Gastroenterol. 2012;107:1693–701.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Ramadas AV, Gunesh S, Thomas GA, et al. Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. Gut. 2010;59:1200–6.

    Article  CAS  PubMed  Google Scholar 

  31. Domenech E, Zabana Y, Garcia-Planella E, et al. Clinical outcome of newly diagnosed Crohn’s disease: a comparative, retrospective study before and after infliximab availability. Aliment Pharmacol Ther. 2010;31:233–9.

    CAS  PubMed  Google Scholar 

  32. Vester-Andersen MK, Michelle V, et al. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol. 2014;109:705–14.

    Article  PubMed  Google Scholar 

  33. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and main- tenance therapy for Crohn’s disease. N Engl J Med. 2005;353:1912–25.

    Article  CAS  PubMed  Google Scholar 

  34. Hanauer SB, Korelitz BI, Rutgeerts P. Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004;127(3):723–9.

    Article  CAS  PubMed  Google Scholar 

  35. Orlando A, Mocciaro F, Renna S. Early post-operative endoscopic recurrence in Crohn’s disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. J Crohns Colitis. 2014;8(10):1217–21.

    Article  PubMed  Google Scholar 

  36. Caprilli R, Cottone M, Tonelli F, et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn’s disease: a pragmatic, double-blind, randomized controlled trial. Aliment Pharmacol Ther. 2003;17(4):517–23.

    Article  CAS  PubMed  Google Scholar 

  37. Cottone M, Cammà C. Mesalamine and relapse prevention in Crohn’s disease. Gastroenterology. 2000;119(2):597.

    Article  CAS  PubMed  Google Scholar 

  38. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136(2):441–50.

    Article  CAS  PubMed  Google Scholar 

  39. Savarino E, Bodini G, Dulbecco P, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn’s disease: a randomized controlled trial. Am J Gastroenterol. 2013;108(11):1731–42.

    Article  CAS  PubMed  Google Scholar 

  40. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn’s disease: report of the working party of the world congresses of gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6:8–15.

    Article  CAS  PubMed  Google Scholar 

  41. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5–36.

    Article  Google Scholar 

  42. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010;139:1147–55.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Gower-Rousseau C, Vasseur F, Fumery M, et al. Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). Dig Liver Dis. 2013;45:89–94.

    Article  PubMed  Google Scholar 

  44. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8:244–50.

    Article  PubMed  Google Scholar 

  45. De Bie CI, Paerregaard A, Kolacek S, et al. Disease phenotype at diagnosis in pediatric Crohn’s disease: 5-year analyses of the EUROKIDS Registry. Inflamm Bowel Dis. 2013;19:378–85.

    Article  PubMed  Google Scholar 

  46. Pigneur B, Seksik P, Viola S, et al. Natural history of Crohn’s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16:953–61.

    Article  PubMed  Google Scholar 

  47. Beaugerie L, Seksik P, Nion–Larmurier I, et al. Predictors of Crohn’s disease. Gastroenterology. 2006;130:650–6.

    Article  PubMed  Google Scholar 

  48. Schoepfer AM, Dehlavi M-A, Fournier N, et al.; On behalf of the Swiss IBD Cohort Study Group. Diagnostic delay in Crohn’s disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol. 2013;108:1744–53

    Google Scholar 

  49. Choi JH, Kim ES, Cho KB, et al. Old age at diagnosis is associated with favorable. Outcomes in Korean patients with inflammatory bowel disease gastrointestinal study group. Intest Res. 2015;13(1):60–7.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Cosnes J, Carbonnel F, Carrat F, et al. Effects of current and former cigarette smoking on the clinical course of Crohn’s disease. J Aliment Pharmacol Ther. 1999;13:1403–11.

    Article  CAS  Google Scholar 

  51. Cottone M, Rosselli M, Pagliaro L, et al. Smoking habits and recurrence in Crohn’s disease. Gastroenterology. 1994;106(3):643–8.

    Article  CAS  PubMed  Google Scholar 

  52. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42(12):1118–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Maus B, Jung C, Mahachie John JM, et al. Molecular reclassification of Crohn’s disease: a cautionary note on population stratification. PLoS One. 2013;17:8(10).

    Google Scholar 

  54. Weedon DD, Shorter RG, Ilstrup DM, et al. Crohn’s disease and cancer. N Engl J Med. 1973;289:1099–103.

    Article  CAS  PubMed  Google Scholar 

  55. Greenstein AJ, Sachar DB, Smith H, et al. A comparison of cancer risk in Crohn’s disease and ulcerative colitis. Cancer. 1981;48:2742–5.

    Article  CAS  PubMed  Google Scholar 

  56. Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100:2724–9.

    Article  PubMed  Google Scholar 

  57. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs. 2007;67:1167–98.

    Article  CAS  PubMed  Google Scholar 

  58. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.

    Article  CAS  PubMed  Google Scholar 

  59. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for non-melanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1621–8.e5.

    Article  CAS  PubMed  Google Scholar 

  60. Beaugerie L, Carrat F, Colombel J-F et al.; and the CESAME Study Group. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2014;63:1416–23

    Google Scholar 

  61. Beaugerie L, Brousse N, Bouvier AM, et al.; CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25

    Google Scholar 

  62. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36–41.

    Article  CAS  PubMed  Google Scholar 

  63. Probert CSJ, Jayanthi V, Wicks ACB. Mortality in Crohn’s disease in Leicestershire, 1972–1989: an epidemiological community based study. Gut. 1992;33:1226–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Canavan C, Abrams KR, Hawthorne B. Long-term prognosis in Crohn’s disease: an epidemiological study of patients diagnosed more than 20 years ago in Cardiff. Alim Pharmacol Therapeut. 2007;25(1):59–65.

    Article  CAS  Google Scholar 

  65. van Staa TP, Card T, Logan RF, et al. 5-aminisalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54(11):1573–8.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Wolters FL, Russel MG, Sijbrandij J, et al.; European Collaborative study group on Inflammatory Bowel Disease (EC-IBD). Crohn’s disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut. 2006;55(4):510–8.

    Google Scholar 

  67. Prior P, Gyde S, Cooke WT, Waterhouse JAH, Allen RN. Mortality in Crohn’s disease. Gastroenterology. 1981;80:307–12.

    CAS  PubMed  Google Scholar 

  68. Weterman IT, Biermond I, Pena AS. Mortality and causes of death in Crohn’s disease. Review of 50 years’ experience in Leiden University Hospital. Gut. 1990;31:1387–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Cottone M, Magliocco A, Rosselli M, et al. Mortality in patients with Crohn’s disease. Scand J Gastroenterol. 1996;31:372–5.

    Article  CAS  PubMed  Google Scholar 

  70. Farrokhyar F, Swarbrik ET, Grace RH, et al. Low mortality in ulcerative colitis and Crohn’s disease in three regional centres in England. Am J Gastroenterol. 2001;96(2):501–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Palermo, Ospedali Riuniti Villa-Sofia Cervello, Via trabucco, 180, Palermo, Italy

    Andrea Affronti, Ambrogio Orlando MD, PhD & Mario Cottone MD, PhD

Authors
  1. Andrea Affronti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ambrogio Orlando MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mario Cottone MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea Affronti .

Editor information

Editors and Affiliations

  1. Radiology Department, Policlinico Paolo Giaccone, Palermo, Italy

    Giuseppe Lo Re

  2. Radiology Department, University of Palermo, Policlinico Paolo Giaccone, Palermo, Italy

    Massimo Midiri

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Affronti, A., Orlando, A., Cottone, M. (2016). Course of Crohn’s Disease. In: Lo Re, G., Midiri, M. (eds) Crohn’s Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-23066-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-23066-5_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-23065-8

  • Online ISBN: 978-3-319-23066-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation